600+ sources. One page. See who else covered it.
NeuroScientific has locked in a key meeting with the US FDA for its StemSmart technology aimed at treating refractory Crohn’s disease in a planned Phase 2 trial.
We haven't written up this one. The Age has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Celltrion said on Aug. 13 that its antibody-drug conjugate (ADC) candidate CT-P73 has received Fast Track designation from the U.S.
“At its current pace, it’s on track to eclipse the West African Ebola outbreak of 2014 to 2016,” WHO chief Tedros Adhanom Ghebreyesus told reporters on Wednesday.
The cells undergo a classic form of plasticity previously thought to occur only in downstream visual circuits.
All three antibody-drug conjugate (ADC)-based anticancer new drug candidates being developed by Celltrion have been named targets for the Fast Track designation by the U.S.
Denmark’s Novo Nordisk, which has led the global pharmaceutical and biotech market on the back of explosive demand for the obesity treatments Wegovy and Ozempic, has run into an unexpected hurdle as…